Vijaya Diagnostic Centre Limited has informed the Exchange regarding Board meeting held on July 28, 2025.
VIJAYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.7 pts more than Nifty Smallcap 250 and 7.1 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vijaya Diagnostic Centre's board approved Q1 FY26 (ended June 30, 2025) financial results, with standalone revenue from operations rising 22.8% YoY to ₹17,484.50 lakhs and standalone profit after tax growing 33% YoY to ₹3,838.94 lakhs (EPS ₹3.74 vs ₹2.74 earlier). Consolidated revenue grew 20.4% YoY to ₹18,805.31 lakhs and consolidated PAT rose 22.5% to ₹3,858.90 lakhs. Operating profitability strengthened, with standalone EBITDA margin expanding to roughly 43.9% from about 41.8% a year ago on better operating leverage. The board also approved a fresh grant of 2,500 ESOPs at ₹780 per option under the VDCL ESOP Plan 2018 and appointed M/s. Balaramakrishna & Associates as the new Secretarial Auditor for five years (FY26–FY30). Statutory auditors B S R and Co. issued an unmodified limited review report on both standalone and consolidated results.
Strong double-digit revenue and earnings growth, combined with margin expansion, signals healthy business momentum and should be viewed positively by shareholders. The secretarial auditor change is a routine governance update and the small ESOP grant is unlikely to cause material dilution.